Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Guangdong Hengrui Pharmaceutical Co: Clinical Trials & FDA Approval Profile

Guangdong Hengrui Pharmaceutical Co (Global / Institutional) sponsors 32 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 24 active protocols (15 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)3.1%
Median Closed Enrollment vs National (145 pts)103 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Guangdong Hengrui Pharmaceutical Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)32
Active Pipeline (Recruiting Now)24 (15)
Completed vs Stopped Early7 / 1 (3.1%)
Median Closed Actual Enrollment103 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Guangdong Hengrui Pharmaceutical Co
Hospital Research SiteLocationShared Protocols
The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, Guangdong3
Xiangya Hospital of Central South UniversityChangsha, Hunan2
Peking University People's HospitalBeijing, Beijing Municipality2

Explore interactive annual charts and M&A subsidiary rollups in the Guangdong Hengrui Pharmaceutical Co Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI